^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Osteosarcoma
    Drug:methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.
    Secondary therapy:
    leucovorin calcium
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/20/2020
    Excerpt:
    Osteosarcoma: Second-line therapy (relapsed/refractory or metastatic disease)…Useful in Certain Circumstances…High-dose methotrexate